Erythrocyte pyruvate kinase deficiency. The influence of physiologically important metabolites on the function of normal and defective enzymes.
The dependence of the erythrocyte pyruvate kinase (PK)-catalyzed reaction on the glycolytic intermediates glucose-6-phosphate (Gluc-6-P), 2,3-diphosphoglycerate (2,3-DPG) and the nucleotides ADP and ATP was studied in normal individuals and 14 patients with PK deficiency. The Gluc-6-P concentrations in the erythrocytes are markedly elevated (4- to 6-fold) in 9 patients with severe hemolytic anemia compared to those 5 exhibiting a mild clinical course (up to 2-fold increased). 2,3-DPG is elevated up to 2 times compared to the controls whereas the measured ADP and ATP only slightly deviate from the normal range. Control experiments showed that these elevations of Gluc-6-P and 2,3-DPG do not depend on the number of reticulocytes. In enzyme kinetic terms, Gluc-6-P shifts the Hill coefficient to smaller values, i.e. suppresses the positive cooperativity (sigmoidal reaction kinetics), found in normal and some of the mutant enzymes and shift the noncooperative enzymes of some patients to an enzyme exhibiting negative cooperativity. The negative cooperativity already present in the enzymes of some of the patients suffering from severe hemolytic anemia becomes more pronounced upon addition of Gluc-6-P. Apparently 2,3-DPG acts as an antagonist to Gluc-6-P in increasing the Hill coefficient, i.e. enhancing the positive cooperativity of the normal enzyme. It shifts the hyperbolic patients' enzymes to a sigmoidal reaction type and the enzymes of those patients with negative cooperativity to a hyperbolic type. ADP and ATP show a similar behavior as 2,3-DPG, but additionally inhibit the enzyme at higher concentrations. The influence of all four phosphates on the Michaelis constant varies depending on the type of cooperativity, in some cases increasing and in some cases decreasing K0.5 PEP. With 7 of the patients, all of them with severe clinical course, a genetic analysis of their R-type PK gene was performed and genetic defects have been identified in the coding sequence. The found changes in the amino acid sequence and their corresponding location in the tertiary structure of the PK subunit can satisfactorily explain the alterations of the regulatory properties of the mutant enzymes thus allowing to establish a good correlation between altered structural and functional properties of the deficient enzyme and the severeness of the course of the disease.
Lakomek
M
M
Universitäts-Kinderklinik, Göttingen, Deutschland.
Winkler
H
H
Pekrun
A
A
Krüger
N
N
Sander
M
M
Huppke
P
P
Schröter
W
W
D019794:2,3-Diphosphoglycerate; D000244:Adenosine Diphosphate / Q000097:blood / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000097:blood / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000494:Allosteric Regulation; D000745:Anemia, Hemolytic, Congenital / Q000201:enzymology*; D002648:Child; D004163:Diphosphoglyceric Acids / Q000097:blood / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004912:Erythrocytes / Q000201:enzymology*; D005260:Female; D019298:Glucose-6-Phosphate; D005958:Glucosephosphates / Q000097:blood / Q000494:pharmacology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007700:Kinetics; D008297:Male; D009154:Mutation; D010728:Phosphoenolpyruvate / Q000097:blood / Q000494:pharmacology; D017434:Protein Structure, Tertiary; D011770:Pyruvate Kinase / Q000097:blood / Q000172:deficiency* / Q000235:genetics; D013329:Structure-Activity Relationship
D004163:Diphosphoglyceric Acids; D004791:Enzyme Inhibitors; D005958:Glucosephosphates; D006454:Hemoglobins; D019794:2,3-Diphosphoglycerate; D019298:Glucose-6-Phosphate; D000244:Adenosine Diphosphate; D010728:Phosphoenolpyruvate; D000255:Adenosine Triphosphate; D011770:Pyruvate Kinase